| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36c0172f6059c0b200188dba42db7fa6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2007-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_127908b467e9e3e4db4cd9d3ed47c142
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c28b3d34dd8ef0268bfaa366f0437743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61463114bd059fb5a8404e25ef6c5c33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ddeb5aad1b24f8a795b3237be5cc184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_663bbf0fc088c06a58327d54e9fc9e52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fd3c6207fc42e4f5c32f24b7fd9d504 |
| publicationDate |
2010-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010062980-A1 |
| titleOfInvention |
Therapeutic uses of beta-antagonists |
| abstract |
Polypeptides derived from Ophiophagus hannah (king cobra) are disclosed together with their use in the treatment of disease, disorder or pathological condition in a patient in need of treatment. The polypeptides disclosed are functionally characterised by their ability to reduce the mammalian heart rate and/or their β-antagonist activity. |
| priorityDate |
2006-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |